治疗慢性移植物抗宿主病药物——belumosudil  

Belumosudil with ROCK-2 inhibition:a new drug for the treatment of chronic graft-versus-host Disease

作　　者：刘悦 张斌[1] 张海英[1] LIU Yue;ZHANG Bin;ZHANG Hai-ying(Department of Pharmacy,Peking University People's Hospital,Beijing 100044,China)

机构地区：[1]北京大学人民医院药学部,北京100044

出　　处：《临床药物治疗杂志》2023年第3期18-22,共5页Clinical Medication Journal

摘　　要：belumosudil是一种Rho相关卷曲螺旋蛋白激酶(ROCK)抑制剂,由Kadmon制药公司开发,用于治疗慢性移植物抗宿主病(cGVHD)和系统性硬化症。2021年7月16日,belumosudil在美国首次获准上市,用于既往至少接受过2次系统一线治疗失败后的cGVHD成人患者和12岁及以上的cGVHD儿童患者。本文从药理作用及作用机制、药动学、临床疗效评价、安全性评价、用法用量等方面对belumosudil进行综述,旨在为临床合理用药提供参考。Belumosudil is a Rho-associated coiled-coil-containing protein kinase(ROCK)inhibitor that has been developed by Kadmon Pharmaceuticals for the treatment of chronic graft-versus-host disease(cGVHD)and systemic sclerosis.It is received its first approval in July 2021 in the US for the treatment of adult and pediatric patients aged≥12 years with cGVHD after failure of at least two prior lines of systemic therapy.This article summarizes the pharmacological effects and mechanisms,pharmacokinetics,clinical efficacy evaluation,safety evaluation,and usage of belumosudil,so as to provide references for clinical rational drug use.

关 键 词：belumosudil 慢性移植物抗宿主病 ROCK2抑制剂 

分 类 号：R973[医药卫生—药品]